BioNTech’s (BNTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $130.00 price target on the stock.

A number of other research firms have also recently commented on BNTX. Truist Financial raised shares of BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. Morgan Stanley increased their target price on shares of BioNTech from $125.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Leerink Partners cut shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 target price for the company. in a research report on Monday, February 2nd. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Finally, TD Cowen decreased their price target on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $133.13.

BioNTech Trading Down 3.2%

NASDAQ:BNTX opened at $102.06 on Monday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The firm has a 50 day moving average of $97.89 and a 200 day moving average of $101.12. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $25.81 billion, a price-to-earnings ratio of -19.48 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. The firm had revenue of $1.06 billion for the quarter. As a group, sell-side analysts anticipate that BioNTech will post -4.41 earnings per share for the current fiscal year.

Insider Activity

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Long Focus Capital Management LLC increased its stake in shares of BioNTech by 91.3% in the third quarter. Long Focus Capital Management LLC now owns 397,655 shares of the company’s stock worth $39,217,000 after acquiring an additional 189,752 shares during the period. Hudson Bay Capital Management LP increased its stake in shares of BioNTech by 36.7% in the third quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company’s stock worth $20,217,000 after acquiring an additional 55,004 shares during the period. Victory Capital Management Inc. increased its stake in shares of BioNTech by 97.0% in the third quarter. Victory Capital Management Inc. now owns 413,685 shares of the company’s stock worth $37,531,000 after acquiring an additional 203,700 shares during the period. LBP AM SA increased its stake in shares of BioNTech by 4.3% in the fourth quarter. LBP AM SA now owns 368,584 shares of the company’s stock worth $35,089,000 after acquiring an additional 15,255 shares during the period. Finally, Lingohr Asset Management GmbH increased its stake in shares of BioNTech by 598.4% in the third quarter. Lingohr Asset Management GmbH now owns 47,643 shares of the company’s stock worth $4,699,000 after acquiring an additional 40,821 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.